WVIC | Jotup

GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022

Retrieved on:

Monday, November 28, 2022

COVID-19, Infection, GeoVax, Cancer, Biotechnology, Patient, Hematological Cancer Research Investment and Education Act, RNA transfection, Immunodeficiency, Vaccine, WVIC, Pharmaceutical industry, Online shopping

ATLANTA, GA, Nov. 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, today announced that Mark J. Newman, Ph.D., Chief Scientific Officer of GeoVax, will present at the World Vaccine & Immunotherapy Congress (WVIC) West Coast 2022, taking place November 28-December 1, 2022, in San Diego, California.

Key Points:

ATLANTA, GA, Nov. 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, today announced that Mark J. Newman, Ph.D., Chief Scientific Officer of GeoVax, will present at the World Vaccine & Immunotherapy Congress (WVIC) West Coast 2022, taking place November 28-December 1, 2022, in San Diego, California.
He will also discuss GeoVaxs COVID-19 vaccine, GEO-CM04S1, which is currently in two Phase 2 clinical trials, one as a more potent primary vaccine for immunocompromised patients and the other trial as a booster vaccine for healthy patients who have previously received an mRNA vaccine.
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the worlds most threatening infectious diseases.
GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades.

Codiak’s Engineered Exosomes Promote T Cell and Antibody Responses to SARS-CoV-2 in vivo, Supporting the Potential for a Broadly Protective Pan-Beta Coronavirus and Variant Vaccine

Retrieved on:

Thursday, December 2, 2021

The study reported the generation of a neutralizing antibody response that showed evidence of activity against multiple SARS-CoV-2 variants.

Key Points:

The study reported the generation of a neutralizing antibody response that showed evidence of activity against multiple SARS-CoV-2 variants.
The results are being presented today at the World Vaccine & Immunotherapy Congress (WVIC) 2021 in San Diego.
Our goal is to advance a pancoronavirus vaccine candidate that has the potential to be broadly protective against infection with SARS-CoV-2, CoV-2 variants and other novel beta coronavirus family members.
This design closely resembles the natural viral structures, and these engineered exosomes stimulated a broad immune response comprising both antibody and T cell-mediated immunity.

BioVaxys Chief Medical Officer David Berd, MD, Invited by Editorial Board of Therapeutic Advances in Vaccines and Immunotherapy to Submit a Review Article on Haptenized Protein Vaccine Platform

Retrieved on:

Thursday, November 18, 2021

Therapeutic Advances in Vaccines and Immunotherapyis a prestigious peer-reviewed journal focused on advances in the fields of vaccinology and immunotherapy, reporting on both prophylactic and therapeutic vaccination as well as other immunotherapeutic interventions.

Key Points:

Therapeutic Advances in Vaccines and Immunotherapyis a prestigious peer-reviewed journal focused on advances in the fields of vaccinology and immunotherapy, reporting on both prophylactic and therapeutic vaccination as well as other immunotherapeutic interventions.
It has a strong clinical, immunological and translational focus, is PubMed, SCOPUS and ESCI-indexed, and is an official partner journal of WVIC.
"We are extremely pleased that Dr Berd is being commissioned to prepare a review article, especially for such a well-regarded publication," says Ken Kovan, President & Chief Operating Officer of BioVaxys.
BioVaxys has multiple issued U.S. patents and pending patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.

BioVaxys Chief Medical Officer David Berd, MD, Invited by Editorial Board of Therapeutic Advances in Vaccines and Immunotherapy to Submit a Review Article on Haptenized Protein Vaccine Platform

Retrieved on:

Thursday, November 18, 2021

Therapeutic Advances in Vaccines and Immunotherapyis a prestigious peer-reviewed journal focused on advances in the fields of vaccinology and immunotherapy, reporting on both prophylactic and therapeutic vaccination as well as other immunotherapeutic interventions.

Key Points:

Therapeutic Advances in Vaccines and Immunotherapyis a prestigious peer-reviewed journal focused on advances in the fields of vaccinology and immunotherapy, reporting on both prophylactic and therapeutic vaccination as well as other immunotherapeutic interventions.
It has a strong clinical, immunological and translational focus, is PubMed, SCOPUS and ESCI-indexed, and is an official partner journal of WVIC.
"We are extremely pleased that Dr Berd is being commissioned to prepare a review article, especially for such a well-regarded publication," says Ken Kovan, President & Chief Operating Officer of BioVaxys.
BioVaxys has multiple issued U.S. patents and pending patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.